Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling, William H K Mukaka, Mavuto Callery, James J Llewelyn, Martin J Cruz, Cintia V Dhorda, Mehul Ngernseng, Thatsanun Waithira, Naomi Ekkapongpisit, Maneerat Watson, James A
Schilling, William H K
Mukaka, Mavuto
Callery, James J
Llewelyn, Martin J
Cruz, Cintia V
Dhorda, Mehul
Ngernseng, Thatsanun
Waithira, Naomi
Ekkapongpisit, Maneerat
Watson, James A
Citations
Altmetric:
Affiliation
William H. K. Schilling ,Mavuto Mukaka,James J. Callery,Martin J. Llewelyn,Cintia V. Cruz,Mehul Dhorda,Thatsanun Ngernseng,Naomi Waithira,Maneerat Ekkapongpisit,James A. Watson,Arjun Chandna,Erni J. Nelwan,Raph L. Hamers, [ ... ],on behalf of the COPCOV Collaborative Group
Other Contributors
Publication date
2024-09-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
No Abstract
Citation
12 September 2024, Bangkok – Four years after being derailed by scientific fraud and politicised science in the first year of the pandemic, COPCOV, the world’s largest COVID-19 chemoprevention study, finally published results today that showed that hydroxychloroquine (HCQ) does have a moderate benefit in preventing COVID-19. Published in PLOS Medicine, COPCOV found a 15% reduction in symptomatic COVID-19 in those taking the medication vs those taking a placebo. The study also showed a significant reduction in all-cause respiratory illness, as well as fewer days lost to work because of illness. Importantly, hydroxychloroquine was well tolerated and safe.
Type
Article
Other
Other